Table 2.

Level of HLA-C expression influences acute GVHD, nonrelapse mortality, and overall mortality, but not relapse

Nonshared HLA-C allotype*	Acute GVHD† (N = 453/1861)		Nonrelapse mortality† (N = 709/1727)		Overall mortality† (N = 1246/1975)		Relapse† (N = 501/1727)
	OR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Patient’s mismatch	1.34 (1.10-1.62)	.003	1.22 (1.06-1.39)	.005	1.15 (1.03-1.27)	.009	1.03 (0.86-1.22)	.76
Donor’s mismatch	1.07 (0.88-1.30)	.49	1.15 (1.01-1.31)	.04	1.14 (1.03-1.26)	.01	0.97 (0.82-1.16)	.74
Sum of mismatched allotypes	1.16 (1.03-1.32)	.02	1.15 (1.06-1.25)	.002	1.12 (1.05-1.19)	.001	1.00 (0.89-1.12)	.96

The level of expression of the patient’s mismatch, the donor’s mismatch, and the sum of these mismatched allotypes were each modeled as a continuous linear variable. ORs and HRs are presented as an increase in risk of failure associated with each increase in expression of 100 fluorescence intensity units.

^*For the shared (matched) allotype, the OR for acute GVHD was 0.90 (95% CI, 0.71-1.13; P = .36), the HR for nonrelapse mortality was 0.85 (95% CI, 0.72-1.00; P = .05), the HR for overall mortality was 0.94 (95% CI, 0.84-1.07; P = .34), and the HR for relapse was 1.10 (95% CI, 0.90-1.34; P = .34).

^†Numbers denote the number of patients with failure for each of the 4 end points of all patients with clinical data for the given end point.